Actionable news
All posts from Actionable news
Actionable news in CYTX: Cytori Therapeutics Inc,

NeuroDerm NDRM acquisition - shares + 14%; Cytori pivotal STAR trial fails - shares plunge 57%.

Price and Volume Movers

NeuroDerm Ltd. (Nasdaq: NDRM) announced that it has signed a definitive agreement under which Mitsubishi Tanabe Pharma Corporation will acquire NeuroDerm for US$39 per share in cash. NeuroDerm currently anticipates the transaction will close in 4Q 2017. Shares closed up 16% to $38.35.

Merck (NYSE: MRK) announced that its Phase 3 Keynote-040 trial investigating KEYTRUDA in previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) did not meet its pre-specified primary endpoint of overall survival (OS) (HR, 0.82 [95% CI, 0.67-1.01]; p = 0.03 [one-sided]). Keytruda was awarded accelerated approval by the FDA in 2016, with the Keynote-040 trial used to confirm efficacy for the approval. Shares are currently trading down 0.9% to $62.57 in the after-hours session.

Cytori Therapeutics, Inc. (NASDAQ:CYTX) shares plummeted to close down 57% to $0.48 following its announcement that top-line data from its pivotal STAR trial of Habeo Cell Therapy in patients with scleroderma did not meet the primary endpoint.

MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX) announced that it intends to explore and evaluate strategic options for the company. The company noted that such options could include the acquisition of MabVax by another...